Our Strategy

Putting the Heart into AI

At Ventripoint Diagnostics Ltd., our mission is to improve outcomes for the world’s cardiac patients of all ages . Our AI-based system turns ultrasound scans into MRI quality models of the heart, in a fraction of the time and cost of MRIs.

Establish leadership in the diagnosis and monitoring of congenital heart defects

Ventripoint was founded to address the challenges of diagnosing and monitoring of congenital heart defects. Our technology is being used to assess patients ranging in age from newborns to the aged. VMS+ is a high-quality, accessible and cost-effective tool that assists with improving the health outcomes of the 13 million CHD patients worldwide.

Expand our scope to additional cardiac indications

VMS+ is able to accurate determine the volumes and ejection fractions of all four chambers of the heart, with class-leading capabilities of measuring function of the right ventricle. Future applications of interest include assessment of cardiotoxicity effects of chemotherapy and pulmonary hypertension.

Enhance capabilities

We are committed to continued improvement in our offering. VMS+ will be further evolved to simplify clinical workflow, provide better reliability and precision, and improve standardization of analysis.